Naringenin has been well documented in managing the cancer cell growth and proliferation, migration, and multi-drug resistance both in in vitro and in vivo by targeting signaling pathways such as Jak/Stat3, Notch1, p38/MAPK, NF-ҡB, PI3K/Akt, and COX2. Here, AKT1 is linked to cancer.